I'm really bullish on FGEN given the upcoming approval for roxadustat in China, which could lead to significant revenue growth. Plus, with the stock currently near $0.35, I see a solid opportunity for it to bounce back to $1. I'm planning to hold for a quick gain based on upcoming catalysts.

I'm bullish on FGEN because of the upcoming China approval for roxadustat that could drive revenue significantly. With supportive fundamentals and institutional interest, I believe this stock can easily rise above $1, potentially reaching $1.50 in the next few months.

With expected approval for Roxadustat in China and consistent financial performance, I believe FGEN will rise significantly above $1 in the next few months. Institutional buys further support this, and insiders are also showing confidence by increasing their stakes.

With strong revenue growth, promising drug pipeline, and analysts upgrading revenue estimates while reducing loss estimates, FGEN presents a compelling long-term investment opportunity.